Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials

• Main Authors: Susanne Paukner (Author), David Mariano (Author), Anita F. Das (Author), Gregory J. Moran (Author), Christian Sandrock (Author), Ken B. Waites (Author), Thomas M. File (Author)
• 格式: 圖書
• 出版: MDPI AG, 2021-12-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Lefamulin was the first systemic pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia based on two phase 3 trials (Lefamulin Evaluation Against Pneumonia [LEAP]-1 and LEAP-2). This pooled analysis evaluated lefamulin efficacy and safety...